Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2006; 12(45): 7319-7325
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7319
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7319
Table 2 Factors associated with recurrence-free survival (Univariate analysis)
| Variables (n) | 5-yr recurrencefree survival (%) | P |
| Age < 50 (151)/> 50 (261) | 58.2/56.4 | 0.58 |
| Sex Male (339)/female(73) | 56.8/58.3 | 0.46 |
| Liver disease etiology | ||
| Alcohol (122)/virus (210)/ Alcohol+virus (41)/others (39) | 64.8/55.1/58.1/40.2 | 0.03 |
| Cirrhosis Present (377)/absent (35) | 58.7/35.7 | 0.001 |
| AFP (μg/L) | ||
| < 200 (281)/200-2000 (73)/> 2000 (33) | 62.9/47.8/26.4 | < 0.0001 |
| ASAT | ||
| Normal (139)/N-2N (129)/> 2N (112) | 59.2/60.5/51.1 | 0.3 |
| ALAT | ||
| Normal (178)/N-2N (116)/> 2N (86) | 56.4/63.5/60.6 | 0.3 |
| Alkaline phosphatase | ||
| Normal (170)/high (200) | 60.9/61.1 | 0.2 |
| G-GT | ||
| Normal (107)/N-2N (113)/> 2N (145) | 66.9/59.9/49.7 | 0.02 |
| Child-Pugh classification | ||
| A (219)/B (125)/C (56) | 58.7/49.6/71.1 | 0.07 |
| Karnofsky index | ||
| > 80% (251)/< 80% (155) | 58.2/55.7 | 0.78 |
| Number of nodules, pre- transplant | ||
| 1 (228)/2 or 3 (142)/> 4 (33) | 58.4/58.4/48.5 | 0.02 |
| Maximum diameter of the largest nodule, pre-transplant | ||
| < 3 cm (126)/3-5 cm (191)/> 5 cm (82) | 69.3/61.4/32.9 | < 0.0001 |
| Sum of tumor diameter (cm) | ||
| < 3 cm (123)/3-5 cm (121)/ 5-10 cm (92)/> 10 cm (34) | 72.1/61.1/50.3/19.5 | < 0.0001 |
| Tumor location, pre- transplant | ||
| Uni-lobar (303)/Bi-lobar (104) | 60.4/48.3 | 0.01 |
| Portal or hepatic vein obstruction, pre-transplant | ||
| Absent (373)/Present (33) | 60.2/27.3 | < 0.0001 |
| Pre or post transplant adjuvant treatment | ||
| Present (274)/absent (136) | 61.1/47.9 | 0.002 |
| Pre LT arterial chemoembolization | ||
| Present (241)/absent (162) | 62.3/53.0 | 0.03 |
| Tumor differentiation | ||
| Well (248)/moderate (91)/poor (19) | 58.3/47.1/42.1 | 0.01 |
| Period of transplantation | ||
| < 91 (82)/91-93 (91)/94-96 (118)/97-98 (121) | 26.8/56.0/61.6/73.3 | < 0.0001 |
| Waiting time | ||
| < 6 mo (318)/6-12 mo (71)/> 12 mo (23) | 55.4/67.1/52.2 | 0.18 |
| Maintenance immunosuppression | ||
| Cyclosporine A (264)/tacrolimus (119) | 52.5/70.8 | 0.003 |
| Steroid-treated rejection | ||
| Yes (125)/no (284) | 48.5/60.8 | 0.003 |
| Use of mono or polyclonal antilymphocyte antibodies | ||
| Present (55)/absent (356) | 45.4/58.8 | 0.02 |
- Citation: Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Compagnon P, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouillères O, Cherqui D, Duvoux C. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 2006; 12(45): 7319-7325
- URL: https://www.wjgnet.com/1007-9327/full/v12/i45/7319.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i45.7319